PCT

NOTIFICATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (CHAPTER I OF THE PATENT COOPERATION TREATY)

(PCT Rule 44bis.1(c))

SHIN, Dong In 304, DUKAM Building, 1457-2, Seocho3-dong, Seocho-gu Seoul 137-867 RÉPUBLIQUE DE CORÉE

From the INTERNATIONAL BUREAU



Date of mailing (day/month/year) 15 June 2006 (15.06.2006)

Applicant's or agent's file reference cu_ext041203

IMPORTANT NOTICE

International application No. PCT/KR2004/003168 International filing date (day/month/year) 03 December 2004 (03.12.2004)

Priority date (day/month/year) 03 December 2003 (03.12.2003)

Applicant

HELIXIR CO., LTD. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

> The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Philippe Becamel

*

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 70 90

Form PCT/IB/326 (January 2004)

PATENT COOPERATION TREA

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference cu_ext041203	FOR FURTHER ACTION	See item 4 below
International application No. PCT/KR2004/003168	International filing date (day/month/year) 03 December 2004 (03.12.2004)	Priority date (day/month/year) 03 December 2003 (03.12.2003)
International Patent Classification (8t See relevant information in Form I	h edition unless older edition indicated) PCT/ISA/237	
Applicant HELIXIR CO., LTD.		

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).				
2.	This REPORT consists of a total of 8 sheets, including this cover sheet.				
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.				
3.	3. This report contains indications relating to the following items:				
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the international application			
	Box No. VIII	Certain observations on the international application			
4.	The International Bureau will conot, except where the applicant date (Rule 44bis .2).	communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority			
		Date of issuance of this report 07 June 2006 (07.06.2006)			

Authorized officer

Telephone No. +41 22 338 70 90

Philippe Becamel

Facsimile No. +41 22 740 14 35 Form PCT/IB/373 (January 2004)


The International Bureau of WIPO · 34, chemin des Colombettes

1211 Geneva 20, Switzerland

PATENT COOPERATION TREATY

From	the

INTERNATIONAL SEARCHING AUTHORITY	
To:	
SHIN, Dong In	
304, DUKAM Building, 1457-2, Seocho3-dong, Seocho-gu Seoul 137-867 Republic of Korea	



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing		
	15 MARCH 2005 (15.03.2005)

FOR FURTHER ACTION

Applicant's or agent's file reference cu ext041203

See paragraph 2 below

International application No. PCT/KR2004/003168 International filing date (day/month/year) 03 DECEMBER 2004 (03.12.2004)

Priority date(day/month/year) 03 DECEMBER 2003 (03.12.2003)

International Patent Classification (IPC) or both national classification and IPC

IPC7 A61K 35/78

Applicant

PANGENOMICS CO., LTD. et al

1.	This	is opinion contains indications relating to the following items:					
	\boxtimes	Box No. I	Basis of the opinion				
		Box No. II	Priority				
		Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
	\boxtimes	Box No. IV	Lack of unity of invention				
	\boxtimes	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
		Box No. VI	Certain documents cited				
	\boxtimes	Box No. VII	Certain defects in the international application				
	\boxtimes	Box No. VIII	Certain observations on the international application				

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220.

For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/KR



Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

YEO, Ho Sup

Telephone No. 82-42-481-5627



International application No.

PCT/KR2004/003168

x No. I Basis of this op		
With regard to the language which it was filed, unless	rage, this opinion has been established on the basis of the state of t	e international application in the language in
This opinion has t	been established on the basis of a translation from the original which is the language of a translation of	ginal language into the following language
Rules 12.3 and 23	The state of the s	d for the purposes of international search (und
With regard to any nucleined invention, this of	cleotide and/or amino acid sequence disclosed in the pinion has been established on the basis of:	international application and necessary to the
a. type of material		
a sequence listin	·	
table(s) related	to the sequence listing	
. format of material		
in wirtten forma	t .	
in computer rea	dable form .	
time of filing/furnishin	-	
contained in the	international application as filed.	
firmished subsec	ith the international application in computer readable for	m.
runnshed subset	quently to this Authority for the purposes of search.	
In addition, in the ca	ase that more than one version or copy of a sequence listi	
— Elad an Ermishad d	and the property of a sequence hate	
med or iurnished, tr	ie required statements that the information in the out-	and the state of t
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subseque filed or does not go beyond the application as filed, as ap	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	ne required statements that the information in the subsequ	ient or additioanl copies is identical to that
in the application as	te required statements that the information in the subsequence filed or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as	ne required statements that the information in the subsequ	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as	te required statements that the information in the subsequence filed or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as diditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as dditional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.
in the application as additional comments:	ee required statements that the information in the subsequifiled or does not go beyond the application as filed, as ap	nent or additioanl copies is identical to that opropriate, were furnished.

International application No. PCT/KR2004/003168

Box No. IV Lack of unity of invention
1. In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has: paid additional fees paid additional fees under protest
not paid additional fees
2. This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is complied with not complied with for the following reasons:
Claims 2-11 concern a pharmaceutical composition, and claims 12-13 concern health care food. Although claims 2-11 and 12-13 are relevant to the composition comprising the same active ingredient, there is no technical relationship between a pharmaceutical composition and a health care food.
Hence, the application contains the following separate groups of inventions not so linked as to form a single general inventive concept (PCT Rule 13.1):
i) Claims 1-11 ii) Claims 1, 12-13
4. Consequently, this opinion has been established in respect of the following parts of the international application:
all parts.
the parts relating to claims Nos.

International application No. PCT/KR2004/003168

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Novelty (N)	Claims	1-13	YES
	Claims		мо
Inventive step (IS)	Claims	1, 9-10	YES
• • •	Claims	2-8, 11-13	NO
Industrial applicability (IA)	Claims	1-13	YES
	Claims		NO

2. Citations and explanations:

The present invention relates to an extract of Cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity, and a composition comprising the same as an active ingredient for the prevention and/or treatment of obesity and adipogenesis—involved diseases.

The following documents have been considered for the purpose of this Written Opinion:

D1 = Korean J. Medicinal Crop Sci. 9(4), 280-283 (2001)

D2 = CN 1092266 A (21.09.1994)

D3 = CN 1079619 A (22. 12. 1993)

D4 = CN 1328778 A (02.01.2002)

1) Novelty & Inventive step

Claims 2-8 and 11-13 relate to a pharmaceutical composition and health care food for the prevention and/or treatment of obesity and adipogenesis—involved diseases, comprising an extract of plant belonged to Cucurbitaceae family as an active ingredient.

D1 describes the anti-hyperlipidemic activity of the water extract of autumn pumpkin(Cucurbita maxima Duchesne) belonged to Cucurbitaceae family.

(Continued on Supplemental Sheet.)

International application No. PCT/KR2004/003168

Ray No VIII	Certain defects in the international application	
MONTH ATT	Cortain derees in the international application	

The following defects in the form or contents of the international application have been noted: Claim 1 is contrary to Rule 6.2(a) because it relies on unnecessary reference to the drawing.

International application No.

PCT/KR2004/003168

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

- 1) In claim 1, "as showen Fig. 12" should be replaced by "as shown Fig. 18".
- 2) The applicants have not supplied data showing that the hexane soluble extracts of Cucurbitaceae family plants as well as the extracts of gourd and cucumber in the present invention are useful for treating and preventing obesity and adipogenesis-involved diseases. Therefore, the subject-matter of claims 3 and 9 is not fairly based on the disclosure of the description including the examples.
- 3) Claims 6, 7 and 12 do not satisfy the requirements of clarity of Article 6 PCT because the obscure expressions such as "and the like" or "non-polar solvent" render the determination of the exact scope of the claims difficult.

International application No.

PCT/KR2004/003168

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box V.

D2-D4 disclose the composition for the prevention and/or treatment of obesity and diabetes mellitus, comprising pumpkin as an active ingredient.

Even though D1-D4 are relevant to the present invention, none of them describe the anti-adipogenic activity of pumpkin belonged to Cucurbitaceae family.

Therefore, the subject-matter of claims 2-8 and 11-13 can be regarded as novel (PCT Article 33(2)).

However, the cited documents D1-D4 already disclose the anti-obesity and anti-hyperlipidemic activity of pumpkin belonged to Cucurbitaceae family.

Therefore, the present invention according to claims 2-8 and 11-13 would be obvious from the teachings of citations D1-D4 to a person skilled in the art. Consequently, the subject-matter of claims 2-8 and 11-13 is not considered to fulfil the requirement of inventive step (PCT Article 33(3)).

Claims 1, 9 and 10 relate to the purified extract isolated from Cucurbitaceae family plant which exhibits the anti-adipogenic and anti-obesity activity, and the pharmaceutical composition comprising the non-polar solvent soluble extract of Cucurbitaceae family plant as an active ingredient for preventing and treating obesity and adipogenesis—involved diseases.

The cited documents D1-D4 do not disclose a non-polar solvent soluble extract of Cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity.

Moreover, the applicants have supplied data showing that the non-polar solvent soluble extract of pumpkin and the purified extract isolated therefrom have the improved pharmacological effects, compared with the water extract of pumpkin.

Consequently, the subject-matter of claims 1, 9 and 10 is novel and is considered to involve an inventive step (PCT Article 33(2)-(3)).

2) Industrial applicability

Claims 1-13 meet the criteria set out in PCT Article 33(4).